TRxADE HEALTH, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
January 16, 2024 at 04:06 pm EST
Share
TRxADE HEALTH, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 2.06 million compared to USD 2.06 million a year ago. Net loss was USD 3.53 million compared to USD 0.503003 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 0.57 a year ago. Basic loss per share was USD 4.57 compared to USD 0.91 a year ago.
For the nine months, sales was USD 5.92 million compared to USD 7.99 million a year ago. Net loss was USD 6.13 million compared to USD 2.55 million a year ago. Basic loss per share from continuing operations was USD 2.83 compared to USD 3.52 a year ago. Basic loss per share was USD 8.65 compared to USD 4.66 a year ago.
TRxADE Health, Inc. provides a technology-enabled health services platform. The Company is focused on digitalizing the retail pharmacy and health services experience by optimizing drug procurement, the prescription journey, access to physicians in the patientâs home and patient engagement in the United States. The Companyâs segments include Trxade, Inc., Integra Pharma Solutions, LLC (IPS) and Superlatus. Trxade, Inc. segment provides a web-based pharmaceutical marketplace platform-business to business (B2B) sales. IPS is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to customers. The Superlatus segment holds Sapientiaâs intellectual property for advanced food extrusion technology and The Urgent Company, which is a manufacturer of ice cream that is animal product-free, vegan, lactose-free, and made with plant-B2B sales. Its subsidiaries include Community Specialty Pharmacy, LLC, Alliance Pharma Solutions, LLC, Bonum Health, LLC and others.